Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $119.00 at Barclays

Protagonist Therapeutics (NASDAQ:PTGX) had its target price upped by Barclays from $113.00 to $119.00 in a report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts also recently issued research reports about the stock. The Goldman Sachs Group increased their price target on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Truist Financial upped their target price on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday. Citigroup lifted their price target on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Finally, Citizens Jmp raised their price objective on Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $107.31.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $101.68 on Thursday. The business’s fifty day moving average price is $86.80 and its 200 day moving average price is $80.59. The firm has a market capitalization of $6.49 billion, a PE ratio of -49.60 and a beta of 2.23. Protagonist Therapeutics has a 1-year low of $39.60 and a 1-year high of $105.69.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). The business had revenue of $7.44 million during the quarter, compared to analyst estimates of $14.92 million. Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. Equities research analysts expect that Protagonist Therapeutics will post 2.43 earnings per share for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 13,151 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the completion of the transaction, the insider directly owned 84,115 shares of the company’s stock, valued at $6,932,758.30. This trade represents a 13.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 34,438 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $82.48, for a total value of $2,840,446.24. Following the transaction, the chief executive officer owned 580,505 shares of the company’s stock, valued at $47,880,052.40. This represents a 5.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 203,167 shares of company stock valued at $16,889,199 in the last quarter. 4.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of large investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC increased its position in Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares in the last quarter. Greenline Wealth Management LLC purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at $27,000. Salomon & Ludwin LLC purchased a new stake in shares of Protagonist Therapeutics in the third quarter valued at $29,000. EverSource Wealth Advisors LLC boosted its stake in shares of Protagonist Therapeutics by 138.9% during the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares during the last quarter. Finally, Abich Financial Wealth Management LLC purchased a new stake in Protagonist Therapeutics during the 3rd quarter worth about $62,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval and commercial terms: Johnson & Johnson’s U.S. FDA approval of ICOTYDE—an oral IL‑23R targeted peptide developed with Protagonist—triggered a $50 million milestone payment to Protagonist and makes the company eligible for 6–10% royalties plus up to $580 million in future milestones, creating a clear near‑ and long‑term revenue path tied to J&J’s commercialization. AccessWire: FDA approval and deal terms
• Positive Sentiment: Major analyst upgrades/price‑target lifts: Several firms raised targets and reiterated positive ratings today—Citigroup to $125 (Buy), Barclays to $119 (Overweight), Leerink to $110 (Outperform), and JPMorgan to $106 (Overweight)—signaling broad Wall Street support and further buying interest. (See links for coverage.) Benzinga: analyst coverage TickerReport: JPMorgan note
• Positive Sentiment: Wall Street commentary: Coverage highlights that J&J’s approval should create “significant value” for Protagonist via milestones and royalties, reinforcing the market narrative that the approval is transformational for PTGX. MSN: Wall Street reaction
• Positive Sentiment: Industry impact commentary: Media coverage frames Protagonist’s first approval as disruptive to larger immunology incumbents, supporting investor expectations of meaningful market share and pricing power if J&J’s launch gains traction. BioSpace: market impact
• Neutral Sentiment: Conference call/transcript and investor materials are available: Protagonist and partners provided conference/webcast materials and a transcript discussing the approval and clinical data; useful for investors wanting primary‑source detail on safety, efficacy, and commercial strategy. Seeking Alpha: transcript Seeking Alpha: slideshow
• Negative Sentiment: Commercial and timing risk: while the approval creates revenue pathways, Protagonist’s near‑term cash flow depends on J&J’s successful launch, market uptake timing, and royalty cadence—factors outside Protagonist’s direct control that could delay or limit realized revenue. AccessWire: deal structure & royalties

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.